Novartis - Recruiting 18 years or older. - Open, Multi-centre, Non-interventional, Observational Study to Characterize the Impact That GI Complaints Have on Patient-reported Outcomes in Patients Who Have Had a Renal Transplant. Patients Will be Evaluated at Visit 1 and Then Again After 4 (+2) Weeks (Visit 2).
East Carolina University - Recruiting 18 years to 75 years. - An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific HLA Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years. - Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pfizer - Recruiting 18 years to 70 years. - A Phase 2, Multicenter, Open-Label, Active Comparator-Controlled, Extension Trial To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 In Renal Allograft Recipients.
Pfizer - Recruiting 18 years to 70 years. - A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients.
Novartis - Recruiting 18 years or older. - 12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certicanr Based Regimen Either in Combination With Cyclosporin A or Tacrolimus.
University of Colorado, Denver - Recruiting 18 years to 70 years. - Differentiating Sirolimus and Everolimus in Combination With Calcineurin Inhibitors in Long-term Maintenance of Kidney Transplant Patients - The Effects on Vascular Endothelial and Kidney Function. The DESIRE Study..
Massachusetts General Hospital - Recruiting 18 years to 70 years. - Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Hoffmann-La Roche - Recruiting 18 years or older. - Prospective, Open-label, Non-interventional Study for the Follow-up of Renal Function in de Novo Kidney Transplant Patients Treated With Immunosuppressive Therapy Containing CellCept in Routine Clinical Practice (ORANGE Study).
BiologicTx, LLC - Recruiting 18 years or older. - Prospective, Multicenter, Observational Registry Study to Determine if Enrollment in a Regional Kidney Paired Donor Exchange Program Improves the Overall Rate of Kidney Transplantation in Sensitized Patients, and Sensitized Patients Undergoing Desensitization Treatments..
Seoul St. Mary's Hospital - Recruiting 20 years or older. - To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients.
Astellas Pharma Inc - Recruiting 5 years to 16 years. - A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prografr Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagrafr Based Immunosuppressive Regimen, Including a Long-Term Follow-Up.
Helsinki University Central Hospital - Recruiting 18 years to 70 years. - Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients.
Asan Medical Center - Recruiting 20 years to 65 years. - Organ Function Preservation by the Combination Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients: OPTIMUM Study.
routine dose tacrolimus and myfortic; low dose tacrolimus and myfortic
Hospital Universitario Ramon y Cajal - Recruiting 18 years to 65 years. - A Pilot Study to Investigate Pharmacokinetic Characteristics of Everolimus in Patients Treated With Tacrolimus-Based Immunosuppression in De Novo Kidney Transplantation.